Inactive Instrument

Highlights AEterna Zentaris Inc. Nasdaq

Equities

CA0079753038

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Jul. 02	Mannatech Names James Clavijo Finance Chief	MT
Jun. 13	Aeterna Zentaris Inc. Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aeterna Zentaris Inc. Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency	Jun. 13	CI
Aeterna and Ceapro Brief: Cos Complete Merger Transaction; New Name Expected to be Announced in Coming Weeks and Details of AGM Expected to be Announced Shortly	Jun. 03	MT
Aeterna Zentaris Inc. completed the acquisition of Ceapro Inc. in a merger of equals transaction.	Jun. 02	CI
Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger	May. 29	MT
Aeterna Zentaris Finalizes Some Details for Ceapro Merger	May. 17	MT
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	May. 17	MT
MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden	May. 14	MT
Aeterna Zentaris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Reverse Split: 1 of 4	May. 02	FA
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	Mar. 28	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	Mar. 28	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	Mar. 27	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	Mar. 27	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	Mar. 27	MT
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	Feb. 26	MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	Dec. 14	MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	Dec. 14	MT
Aeterna Zentaris Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Aeterna Zentaris Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AEterna Zentaris Inc. Nasdaq

Equities

CA0079753038

Highlights

Filters